Search
Terns Pharmaceuticals Inc
TERNAdd to Watchlist
52.950USD
0.0000.00%
Close 05/13, 16:00（ET）Quotes delayed by 15 min
6.12BMarket Cap
LossP/E TTM
More Details of Terns Pharmaceuticals Inc Company
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
Terns Pharmaceuticals Inc Info
Ticker SymbolTERN
Company nameTerns Pharmaceuticals Inc
IPO dateFeb 05, 2021
CEOBurroughs (Amy L)
Number of employees59
Security typeOrdinary Share
Fiscal year-endFeb 05
Address1065 East Hillsdale Blvd., Suite 100
CityFOSTER CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94404
Phone16505255535
Websitehttps://ternspharma.com/
Ticker SymbolTERN
IPO dateFeb 05, 2021
CEOBurroughs (Amy L)
Company Executives of Terns Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David Fellows
Mr. David Fellows
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
--
--
Ms. Hongbo Lu, Ph.D.
Ms. Hongbo Lu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Quigley, J.D.
Ms. Jill M. Quigley, J.D.
Independent Director
Independent Director
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Independent Director
Independent Director
--
--
Dr. Emil T. Kuriakose, M.D.
Dr. Emil T. Kuriakose, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Amy L. Burroughs
Ms. Amy L. Burroughs
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Sun (Melita) Jung
Ms. Sun (Melita) Jung
Chief Business Officer
Chief Business Officer
--
--
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Independent Director
Independent Director
--
--
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David Fellows
Mr. David Fellows
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
--
--
Ms. Hongbo Lu, Ph.D.
Ms. Hongbo Lu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Quigley, J.D.
Ms. Jill M. Quigley, J.D.
Independent Director
Independent Director
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Independent Director
Independent Director
--
--
Dr. Emil T. Kuriakose, M.D.
Dr. Emil T. Kuriakose, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Morgan Stanley & Co. LLC
6.77%
BlackRock Institutional Trust Company, N.A.
5.73%
Adage Capital Management, L.P.
4.80%
Vivo Capital, LLC
4.45%
Vestal Point Capital, LP
3.90%
Other
74.35%
Shareholders
Shareholders
Proportion
Morgan Stanley & Co. LLC
6.77%
BlackRock Institutional Trust Company, N.A.
5.73%
Adage Capital Management, L.P.
4.80%
Vivo Capital, LLC
4.45%
Vestal Point Capital, LP
3.90%
Other
74.35%
Shareholder Types
Shareholders
Proportion
Investment Advisor
31.48%
Investment Advisor/Hedge Fund
30.63%
Hedge Fund
28.80%
Research Firm
9.56%
Venture Capital
5.23%
Private Equity
2.14%
Pension Fund
1.67%
Bank and Trust
0.35%
Sovereign Wealth Fund
0.34%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
478
133.90M
115.93%
+29.44M
2025Q4
376
92.69M
87.28%
-19.26M
2025Q3
346
91.95M
105.09%
-23.09M
2025Q2
344
88.08M
100.66%
-23.35M
2025Q1
352
90.67M
103.82%
-24.88M
2024Q4
339
91.95M
108.28%
-13.40M
2024Q3
310
84.11M
100.51%
-7.48M
2024Q2
277
70.14M
99.60%
-17.86M
2024Q1
253
68.60M
105.57%
-10.37M
2023Q4
237
68.12M
109.36%
-7.25M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Morgan Stanley & Co. LLC
7.83M
6.78%
+287.70K
+3.82%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
6.61M
5.73%
+1.58M
+31.36%
Dec 31, 2025
Adage Capital Management, L.P.
5.55M
4.81%
+1.61M
+40.90%
Dec 31, 2025
Vivo Capital, LLC
5.14M
4.46%
-204.91K
-3.83%
Jan 31, 2026
Vestal Point Capital, LP
4.50M
3.9%
+4.50M
--
Dec 31, 2025
Avoro Capital Advisors LLC
4.35M
3.77%
+4.35M
--
Dec 31, 2025
Janus Henderson Investors
3.38M
2.93%
+3.38M
--
Dec 31, 2025
Citadel Advisors LLC
3.17M
2.74%
+1.58M
+99.24%
Dec 31, 2025
Capitolis Liquid Global Markets LLC
3.05M
2.64%
+3.05M
--
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Roundhill GLP-1 & Weight Loss ETF
2.84%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.44%
Virtus LifeSci Biotech Clinical Trials ETF
1.42%
State Street SPDR S&P Pharmaceuticals ETF
0.83%
Tema Oncology ETF
0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
0.39%
ALPS Medical Breakthroughs ETF
0.3%
ProShares Ultra Nasdaq Biotechnology
0.3%
iShares Russell 2000 Value ETF
0.13%
iShares Micro-Cap ETF
0.11%
View more
Roundhill GLP-1 & Weight Loss ETF
Proportion2.84%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.44%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.42%
State Street SPDR S&P Pharmaceuticals ETF
Proportion0.83%
Tema Oncology ETF
Proportion0.52%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.39%
ALPS Medical Breakthroughs ETF
Proportion0.3%
ProShares Ultra Nasdaq Biotechnology
Proportion0.3%
iShares Russell 2000 Value ETF
Proportion0.13%
iShares Micro-Cap ETF
Proportion0.11%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
